Triple combination antimicrobial regimen in the treatment of infections of neutropenic cancer patients

J Exp Clin Cancer Res. 1997 Sep;16(3):321-4.

Abstract

Twenty-six cancer patients (pts) with chemotherapy-related neutropenic fever were treated with vancomycin 30 mg/m2/day i.v. every 12 hrs, imipenem 1500 mg/day i.v. every 8 hrs, and pefloxacin 800 mg/day i.v. every 12 hrs. Twelve fevers of unknown origin (FUO), 10 gram-positive, 3 gram-negative and 1 mycoplasma were also treated. Globally, cure was observed in 22 pts (84%) and failure in 4 pts (16%); in gram-positive infections alone, cure was observed in 10 pts (80%) and failure in 4 pts (20%). Defervescence was obtained within 3 days in 77% pts. No relevant side effects were observed.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Drug Therapy, Combination / therapeutic use*
  • Fever / drug therapy
  • Fever / etiology
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / etiology
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / etiology
  • Humans
  • Imipenem / therapeutic use*
  • Mycoplasma Infections / drug therapy*
  • Mycoplasma Infections / etiology
  • Neoplasms / complications*
  • Neoplasms / drug therapy
  • Neoplasms / microbiology*
  • Neutropenia / chemically induced*
  • Neutropenia / drug therapy
  • Neutropenia / microbiology*
  • Pefloxacin / therapeutic use*
  • Thienamycins / therapeutic use*
  • Vancomycin / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antineoplastic Agents
  • Thienamycins
  • Pefloxacin
  • Vancomycin
  • Imipenem